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 Annex 1: Harmonisation of drinking amount across the contributing studies 
 
Emerging Risk Factors Collaboration 
Data on alcohol was harmonised across studies in the ERFC through consensus with individual study collaborators. 
Studies used a variety of methods to record alcohol consumption (eg, self-administered vs interview-led questionnaires; 
food frequency questionnaires vs dietary recall surveys) to provide information on alcohol consumption for different types 
of alcoholic drinks (ie, beer, wine, cider, spirits/liquor, alcopops, long drink, fortified wine, liqueur, sake, shochu, tharra, 
aperitif/digestif) and in various formats (eg, amount in a given period, frequency of drinks in a given period, categories 
for amount or frequency), eTable 1. The available information was harmonised into the following variables (in order of 
precedence): amount, status, duration, stop age, start age, years stopped, usage frequency. Mid-points of bounded 
categories or lower bounds of categories without an upper bound for alcohol amount were used to convert information to 
a continuous scale. Alcohol status was categorised as “never”, “never/ex”, “ex”, “ex/current” and “current” drinkers. The 
alcohol status categories “never/ex” and “ex/current” included studies that did not definitively distinguish between never 
and ex drinkers, or between ex and current drinkers, respectively. Subsequently, drinking amount was set to missing for 
participants with “ex/current” drinking status as it was not possible to distinguish current drinking amount. Information 
on alcohol amount was converted to a UK standard scale of grams/week (1 unit=8 grams of ethanol). Alcohol status and 
amount were cross-referenced with each other to resolve ambiguous data and update missing information.  
EPIC-CVD 
Intake of alcoholic beverages at baseline was calculated from validated country-specific dietary questionnaires aimed to 
capture specificity of local dietary habits. The number of standard glasses of beer, cider, wine, sweet liquor, distilled 
spirits or fortiﬁed wines consumed per day/week during the 12 months prior to recruitment were reported by participants. 
In each country, intake was calculated based on the estimated ethanol content and average glass volume for each type of 
alcoholic beverage1. To this purpose, information from highly standardized 24-hr dietary recalls from a subset of the 
cohort was used. Information on lifetime alcohol intake were collected with lifestyle questionnaires administered at 
baseline. Information on lifetime alcohol consumption was assessed as number of glasses of different beverages consumed 
at 20, 30, 40 and 50 years of age consumed per week, and then computed as a weighted average and expressed as grams 
per week. Information on alcohol amount was then converted to a standard scale of grams/week (1 unit=8 grams of 
alcohol). 
UK Biobank 
Intake of alcoholic beverages at baseline was obtained from a touchscreen questionnaire which was used to extract 
information on status, intake frequency (per month) and beverage type (ie, red wine, white wine/champagne, beer, spirits, 
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fortified wine). See https://biobank.ctsu.ox.ac.uk/crystal/docs/TouchscreenQuestionsMainFinal.pdf.  Information on total 
alcohol amount was then calculated and converted to a standard scale of grams/week (1 unit=8 grams of alcohol). 
 
1Bergmann MM, Rehm J, Klipstein-Grobusch K, Boeing H, Schütze M, Drogan De , et al. The association of pattern of 
lifetime alcohol use and cause of death in the European prospective investigation into cancer and nutrition (EPIC) study. 
Int J Epidemiol. 2013;42(6): 1772–1790.  
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Annex 2 ERFC Study Acronyms  
 
ARIC, Atherosclerosis Risk in Communities Study 
AFTCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study 
ATENA, cohort of Progetto CUORE 
ATTICA, ATTICA study 
AUSDIAB, Australian Diabetes, Obesity and Lifestyle Study 
BHS, Busselton Health Study 
BRUN, Bruneck Study 
BWHHS, British Women's Heart and Health Study 
CAPS, Caerphilly Prospective Study 
CASTEL, Cardiovascular Study in the Elderly 
CHARL, Charleston Heart Study 
CHS1, CHS2, Cardiovascular Health Study I and II 
COPEN, Copenhagen City Heart Study 
DESIR, Data from an Epidemiological Study on the Insulin Resistance Syndrome 
DRECE, Diet and Risk of Cardiovascular Disease in Spain 
DUBBO, Dubbo Study of the Elderly 
EAS, Edinburgh Artery Study 
EPESEBOS, The Established Populations for the Epidemiologic Study of the Elderly Studies, Boston 
EPESEIOW, The Established Populations for the Epidemiologic Study of the Elderly Studies, Iowa 
EPESENCA, The Established Populations for the Epidemiologic Study of the Elderly Studies, North 
Carolina 
EPESENHA, The Established Populations for the Epidemiologic Study of the Elderly Studies, New Haven 
ESTHER, Epidemiologische Studie zu Chancen der Verhutung und optimierten Therapie chronischer 
Erkrankungen in der alteren Bevolkerung 
FINMARK, cohort of CONOR 
FINRISK92, Finrisk Cohort 1992 
FINRISK97, Finrisk Cohort 1997 
FLECTHER, Fletcher Challenge Blood Study 
FUNAGATA, Funagata Study 
GOLSTRUP, Golstrup Study 
GREPCO, cohort of Risk Factors and Life Expectancy Pooling Project 
HBS, Helsinki Businessmen Study 
HCS, Hertfordshire Cohort Study 
HIMS, Health in Men Study 
HISAYAMA, Hisayama Study 
HONOL, Honolulu Heart Program 
HUBRO, cohort of CONOR 
IKNS, Ikawa, Kyowa, and Noichi Study 
KARELIA, North Karelia Project 
KIHD, Kuopio Ischaemic Heart Disease Study 
LASA, Longitudinal Aging Study Amsterdam 
MATISS83/87/93, cohort of Progetto CUORE 
MESA, Multi-Ethnic Study of Atherosclerosis 
MCVDRFP, Monitoring of CVD Risk Factors Project 
MICOL, cohort of Risk Factors and Life Expectancy Pooling Project 
MONICA_KORA1, MONICA/KORA Augsburg Surveys S1 
MONICA_KORA2, MONICA/KORA Augsburg Surveys S2 
MONICA_KORA3, MONICA/KORA Augsburg Surveys S3 
MORGEN, Monitoring Project on Chronic Disease Risk Factors 
MRCOLD,  MRC Study of Older People 
MRFIT, Multiple Risk Factor Intervention Trial 1 
NFR, cohort of Risk Factors and Life Expectancy Pooling Project 
NHANES I, First National Health and Nutrition Examination Survey 
NHANES III, Third National Health and Nutrition Examination Survey 
NPHSII, Northwick Park Heart Study II 
NSHS, Nova Scotia Health Survey 
OPPHED, cohort of CONOR 
OSAKA, Osaka Study 
OSLO, Oslo Study 
PRHHP, Puerto Rico Heart Health Program 
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PRIME, Prospective Epidemiological Study of Myocardial Infarction 
PROCAM, Prospective Cardiovascular Münster Study 
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk 
QUEBEC, Quebec Cardiovascular Study 
RANCHO, Rancho Bernardo Study 
RS_I, The Rotterdam Study I 
RS_II, The Rotterdam Study II 
RS_III, The Rotterdam Study III 
SHHEC, Scottish Heart Health Extended Cohort 
SHIP, Study of Health in Pomerania 
TOYAMA, Toyama Study 
TROMS, cohort of CONOR 
TROMSØ, Tromsø Study 
ULSAM, Uppsala Longitudinal Study of Adult Men 
WHITE I, Whitehall I Study 
WHITE II, Whitehall II Study 
WHIHABPS, Women's Health Initiative (Hormones and Biomarkers Predicting Stroke in Women) 
WCWC, Wurttemberg Construction Worker Cohort 
WOSCOPS, West of Scotland Coronary Prevention Study 
ZUTE, Zutphen Elderly Study 
 
 
ATHENA, and MATISS are part of the CUORE study  
FINNMARK, HUBRO, OPPHED, OSLO2, and TROMS are part of the CONOR study 
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Annex 3: Definitions of major incident outcomes considered  
 
End point (includes both fatal and non-fatal) ICD-10 codes 
All cardiovascular  G45, I01, I03-I82, I87, I95-I99, F01, Q20-
Q28, R96 
Myocardial infarction (MI) I21, I22, I23 
Coronary disease non-MI I24-I25 
All stroke F01, I60-I69 
Ischaemic stroke I63 
Haemorrhagic stroke I61 
Subarachnoid stroke I60 
Unclassified stroke† I64  
Heart failure I50 
Other vascular deaths I47-I49, I10-I15, R96, I71, I50 
Cardiac dysrhythmia  I47-I49 
Hypertensive disease I10-I15 
Sudden death R96 
Aortic aneurysm  I71 
† Unclassified stroke refers to ICD codes I64 (ICD-10), 436 (ICD-9) or earlier ICD equivalents, or strokes not specified 
as ischemic or haemorrhagic in study specific codes.  
Corresponding ICD-6, 7 or 8 codes are used for ERFC studies that recorded outcomes using earlier ICD versions. 
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eAnnex 4. Statistical methods used for estimating years of life lost 
 
We used three pieces of information to estimate reductions in life expectancy associated with alcohol consumption at 
baseline (henceforth “exposure groups” pre-defined as alcohol consumption >0-≤100,  >100-≤200, >200-≤350 and >350 
grams/week):  
(i) age-at-risk specific hazard ratios for all-cause (and cause-specific) mortality in each exposure group versus the 
reference (derived from the ERFC and UK Biobank);  
(ii) population all-cause (and cause-specific) mortality rates (derived from the detailed mortality component of the CDC 
WONDER database of the US Centers for Disease Control and Prevention); and  
(iii) prevalence of exposure groups in the population (derived from the ERFC and UK Biobank).  
 
We estimated population survival curves for each exposure group, utilising estimated age-at-risk specific hazard ratios 
for mortality by exposure groups in the ERFC, and UK Biobank and routine statistics on overall population mortality 
rates. We estimated reductions in life-expectancy as differences in areas under any two survival curves compared. To 
calculate an appropriate mortality rate for the reference group (i.e. defined as those drinking >0-≤100 grams/week), we 
used ERFC and UK Biobank data on exposure prevalence estimates, as described below. 
 
Age-at-risk specific hazard ratios for mortality by exposure groups were estimated from ERFC and UK Biobank data 
separately for each sex. Specifically, a Cox regression model stratified by cohort and trial arm (where applicable) was 
fitted separately for each sex using a dataset in which participant ages-at-risk were deterministically updated by splitting 
the follow up times every 5-years and recalculating an age-at-risk variable at the beginning of each 5-year interval of 
follow up. Interactions between baseline exposure groups and linear and quadratic terms for the age-at-risk variable were 
included in the model to obtain smoothed hazard ratios. Thus, for participant i  in stratum s  with exposure group 
indicator variable ( )si jE  (i.e. dummy variable equal to 1 if in exposure group is j  and zero otherwise) the log hazard 
rate at time t  since baseline was modelled as: 
7 7 7
2 2
0 0 ( ) 2 3 1 ( ) 2 ( )
1 1 1
log( ( )) log( ( ))si s j si j si si j si j si j si j si
j j j
h t h t E agerisk agerisk E agerisk E agerisk    
  
             (1) 
from which the age-at-risk specific hazard ratios (and 95% CIs) for mortality were obtained as linear combinations of the 
relevant estimated coefficients, with age-at-risk fixed at values corresponding to midpoints of 5-year age-groups from age 
40 onwards. 
 
Population all-cause (and cause-specific) mortality rates per 100,000 were obtained in 5-year age-groups for the US 
population during years 2007-2010 from the Center for Disease Control (CDC) WONDER online database 
(http://wonder.cdc.gov/controller/datarequest/D76), as well as for 15 EU countries during year 2000 
(http://ec.europa.eu/eurostat/data/database). Because the mortality rates were provided only up to age-group 80-84 years, 
but we desired to estimate the overall population survival curves, we used a Poisson regression model with linear and 
quadratic terms for the midpoints of 5-year age-groups to smooth and extrapolate the mortality rates. Next, assuming 
exponential survival (i.e. constant hazard) within each 5-year age group, we estimated the age-specific survival probability 
as  and derived the overall population survival curves from age 35 onwards as the product of the 
relevant age-group specific survival probabilities. 
exp( 5 )a aS IR  
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 (2) 
In order to infer population mortality rates appropriate for the reference exposure group used in our estimation of age-
specific hazard ratios (i.e. defined as those drinking >0-≤100 grams/week), we used logistic regression to model the age-
specific prevalence of the alchol consumption categories in ERFC and UK Biobank cohorts by sex and decade of 
recruitment. We used the age-specific prevalence estimates for the decade commencing in the year 1990 to infer the age-
specific mortality rates appropriate for our reference group 
0aIR  as:
1 
 (3) 
Where 
aIR  is the population mortality rate for age group a , ajp  is  the age-specific prevalence of exposure group j , 
and ajRR  is  the age-specific hazard ratio in comparison of exposure group j  versus reference group ( 0j  ). The age-
specific mortality rates in each of the non-reference exposure groups were then inferred in turn by multiplying the age-
specific mortality rate for the reference group 
0aIR  by the age-specific hazard ratios ajRR  based on ERFC and UK 
Biobank data and equation (2) above used to infer the exposure group-specific population survival curves. Finally, 
reductions in life expectancy according to baseline exposure groups were estimated as difference in the areas under the 
survival curves for the reference group and each of the non-reference exposure groups in turn. The areas under curves 
were calculated by numerical integration. 
 
Monte Carlo simulation was used to calculate confidence intervals for the estimated reductions in life expectancy, taking 
into account uncertainty in the age-at-risk specific hazard ratios calculated from equation (1) above. In particular, new 
parameter estimates were randomly drawn from the multivariate normal distribution defined by the fitted model mean 
and covariance matrix, 200 times, and the above procedure repeated for each draw to calculate reductions in life-
expectancy for each index age of interest. Assuming asymptotic normality, the standard deviation of the 200 Monte Carlo 
estimates of reductions in life expectancy for each index age were used to calculate 95% confidence intervals around the 
originally estimated value. Histograms were inspected to judge that normality assumption was reasonable. 
  
Appendix References 
 1 Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: putting 
health risks in context. J Natl Cancer Inst 2008;100(12):845-53. 
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Supplementary Tables/Figures 
 
eTable 1: Alcohol consumption ascertainment methods for 83 studies in the ERFC, EPIC-CVD and UK Biobank. 
 
eTable 2: Summary of individual-level baseline characteristics. 
 
eTable 3: Summary of events for each study (83 studies), restricted to current drinkers with information on alcohol 
amount, age and sex. 
 
eTable 4. Comparison of baseline characteristics of individuals used in main analysis versus individuals with repeat 
measures of alcohol consumption or measures of lifetime alcohol consumption from the contributing data sources. 
 
eTable 5. Hazard ratios for cardiovascular outcomes amongst current drinkers, without and with adjustment for usual 
levels of potential confounders, mediators and proxies thereof.  
 
eTable 6. Hazard ratios for death from lung cancer and digestive related cancer outcomes per 100 grams/wk higher 
average alcohol consumption amongst current drinkers, without and with adjustment for potential confounders, 
mediators and proxies thereof. 
 
eTable 7: Sex-specific hazard ratios for major cardiovascular outcomes  per 100 grams/week increase in average 
alcohol consumption amongst current drinkers.  
 
eTable 8: Sensitivity analyses: Hazard ratios for major cardiovascular outcomes  per 100 grams/week increase in 
average alcohol consumption amongst current drinkers. 
 
eTable 9: Baseline characteristics by frequency of alcohol consumption. 
 
eTable 10: Baseline characteristics by type of alcohol predominantly consumed. 
 
eFigure 1: Flow diagram of study selection process in current analysis. 
 
eFigure 2: Box plots of baseline alcohol consumption amongst current drinkers from 83 studies by decade of first 
baseline survey.   
 
eFigure 3a: Cross-sectional associations between baseline alcohol consumption and continuous baseline characteristics.  
 
eFigure 3b: Cross-sectional associations between baseline consumption and categorical baseline characteristics.  
 
eFigure 4: Shape of association of average alcohol consumption with all-cause mortality and all cardiovascular disease 
amongst current drinkers. 
 
eFigure 5. Shape of association of baseline alcohol consumption with all-cause mortality for males and females.  
 
eFigure 6. Shape of association of baseline alcohol consumption with all-cause mortality by age-specific groups.  
 
eFigure 7. Shapes of associations of usual alcohol consumption with death from other cardiovascular causes.  
 
eFigure 8. Shapes of associations of baseline alcohol consumption with type of stroke. 
 
eFigure 9a: Hazard ratios per 100 grams/week higher average alcohol consumption for subtypes of cardiovascular 
outcomes amongst current drinkers, adjusted for body mass index. 
 
eFigure 9b. Shape of association of average alcohol consumption with all-cause  
mortality and all cardiovascular disease amongst current drinkers, adjusted for body mass index. 
 
eFigure 10: Shape of association between baseline alcohol consumption, including ex- and non-drinkers, with all 
cardiovascular disease. 
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eFigure 11: Hazard ratios per 100 grams/week higher baseline alcohol consumption for subtypes of cardiovascular 
outcomes amongst current drinkers with recorded baseline alcohol consumption (left) compared against all current 
drinkers using multiple imputation (right). 
 
eFigure 12: Shapes of associations of average alcohol consumption with stroke and coronary outcomes amongst 
alcohol drinkers.  
 
eFigure 13: Best fitting 2nd degree fractional polynomial for the modelled shape of association between baseline 
alcohol consumption with all-cause mortality.  
 
 
eFigure 14: Hazard ratios per 100 grams/week higher average alcohol consumption for subtypes of cardiovascular 
outcomes amongst current drinkers from a fixed effect meta-analysis. 
 
eFigure 15: Hazard ratios per 100 grams/week higher average alcohol consumption for subtypes of cardiovascular 
outcomes amongst current drinkers, from fixed effects analysis with inclusion of studies with fewer than 5 outcomes of 
a particular type*. 
 
eFigure 16: Shape of association between baseline alcohol consumption with major vascular restricted to ERFC studies 
recording both coronary death and non-fatal MI endpoints. 
 
eFigure 17: Shapes of associations of baseline alcohol consumption with all-cause mortality by (a) consumption 
frequency, (b) consumption type and (c) binge drinking status. 
 
eFigure 18: Hazard ratios per 100 grams/week higher alcohol consumption for all-cause mortality and different 
cardiovascular outcomes amongst current drinkers and by alcohol type. 
 
 
eFigure 19a-e: Hazard ratios per 100 gram/week increase in usual alcohol consumption for major  vascular outcomes 
and all cause mortality amongst current drinkers by study/cohort-level characteristics.  
 
eFigure 20a-e: Hazard ratios per 100 gram/week increase in average alcohol consumption for major  cardiovascular 
outcomes amongst current drinkers by individual-level characteristics.  
 
eFigure 21. Funnel plots and assessment of small-study effects for study-specifc hazard ratios per 100 gram/week 
increase in usual alcohol consumption for major  vascular outcomes amongst current drinkers. 
 
eFigure 22. Estimated future years of life lost by extent of baseline alcohol consumption compared to participants who 
consume less than the hypothetical alcohol consumption threshold.  
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Study Ascertainment method of 
alcohol consumption 
Format of ascertainment Calculated or 
Reported1 
AFTCAPS Questionnaire Self administered Calculated 
ARIC Dietary Survey Interview Calculated 
ATENA FFQ Self administered Reported 
ATTICA FFQ Self administered Calculated 
AUSDIAB FFQ Self administered Calculated 
BHS Lifestyle questionnaire Self administered Reported 
BRUN 
Questionnaire 
FFQ 
Diet record 
Interview 
Interview 
Self administered 
 
Calculated 
BWHHS Questionnaire Self administered Calculated 
CAPS Questionnaire Unknown Calculated 
CASTEL  Questionnaire Self administered Reported 
CHARL  Dietary Survey/ questionnaire Interview/ Self administered Calculated 
CHS1 Unknown Unknown Calculated 
CHS2  Unknown Unknown Calculated 
COPEN  Questionnaire Self administered reported 
DESIR Questionnaire Self administered Unknown 
DRECE  24hr recall & FFQ Interview Calculated 
DUBBO Questionnaire Interview Calculated 
EAS  Questionnaire Self administered Calculated 
EPESEBOS Questionnaire Interview Reported 
EPESEIOW Questionnaire Interview Reported 
EPESENCA Questionnaire Interview Reported 
EPESENHA Questionnaire Interview Reported 
EPIC-CVD 24hr recall, FFQ, 7-day diary Interview & s elf administered Calculated 
ESTHER FFQ Self administered Calculated 
FINNMARK Questionnaire Self administered Unknown 
FINRISK92 Questionnaire Self administered Reported 
FINRISK97 Questionnaire Self administered Reported 
FLETCHER  Questionnaire Self administered Calculated 
FUNAGATA  Unknown Unknown Unknown 
GLOSTRUP Questionnaire Self administered Calculated  
GREPCO Questionnaire Self administered Reported 
HBS FFQ Self administered Calculated  
HCS Questionnaire Self administered Unknown 
HIMS Questionanire Self administered 
Reported 
HISAYAMA FFQ Self administered Calculated 
HONOL  Questionnaire Interview Calculated 
HPFS  FFQ Self administered Calculated 
HUBRO Questionnaire Self administered Calculated 
IKNS  Questionnaire Interview Calculated 
KARELIA Questionnaire Self administered Calculated 
KIHD  Questionnaire Self administered Reported 
LASA  Questionnaire Interview Calculated 
MATISS83 FFQ & dietary recall Self administered/ Interview Reported 
MATISS87 FFQ & dietary recall Self administered/ Interview Reported 
MATISS93 FFQ & dietary recall Self administered/ Interview Reported 
MCVDRFP Questionnaire Self administered Calculated 
MESA FFQ Interview/ Self administered Calculated 
MONICA_KORA1 Dietary Survey Interview 
Calculated 
MONICA_KORA2 Dietary Survey Interview 
Calculated 
MONICA_KORA3 Dietary Survey Interview 
Calculated 
MICOL Questionnaire Self administered Reported 
MRCOLD  Questionnaire Interview Calculated 
MRFIT 
 
 
Questionnaire 
 
 
Self administered Calculated 
 
 
 
 
 
 
   
eTable 1: Alcohol consumption ascertainment methods for 83 studies in the ERFC, EPIC-CVD and UK 
Biobank. 
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Continued over page 
 
 
 
1Calculated: alcohol amount is the product of the reported frequency (eg, more than once per day, more 
than once per month) and the individual reported intake per occasion (eg, 2 glasses on each occasion. 
Reported: alcohol amount is provided within a specified time period (eg, number of glasses in the past 
week) 
FFQ=food frequency questionnaire.
Study Ascertainment method of 
alcohol consumption 
Format of ascertainment Calculated or 
Reported1 
NFR Unknown Self administered Reported 
NHANESI Questionnaire Interview Calculated 
NHANESIII Questionnaire Interview Calculated 
NPHSII  Questionnaire Self administered Calculated 
NSHS  FFQ Self administered Reported 
OPPHED Questionnaire Self administered Calculated 
OSAKA  Questionnaire Interview Calculated 
OSLO2 Questionnaire Self administered Unknown 
PRHHP 24 hr recall Interview Calculated 
PRIME 
Quantitative recall frequency 
questionnaire 
Interview 
Calculated 
PROCAM  Questionnaire Unknown Calculated 
PROSPER  Questionnaire Unknown Calculated 
QUEBEC  Questionnaire Self administered Calculated 
RANCHO Questionnaire Interview Calculated 
RS-I  Dietary interview Interview Calculated 
RS-II Dietary interview Interview Unknown 
RS-III Dietary interview Interview Unknown 
SHHEC 7 day recall Self administered Calculated 
SHIP Unknown Unknown Unknown 
TOYAMA  Questionnaire Self administered Unknown 
TROMS Questionnaire Self administered Unknown 
TROMSØ Questionnaire Self administered Calculated 
ULSAM  FFQ Self administered Reported 
UK Biobank Questionnaire Self administered Reported 
WCWC  Questionnaire Interview Unknown 
WHIHABPS  FFQ Self administered Calculated 
WHITEI  FFQ/ Dietary recall Self administered Calculated 
WHITEII FFQ Self administered Calculated 
WOSCOPS  Dietary recall Self administered Reported 
ZUTE Cross-check dietary history Interview Calculated 
    
    
eTable 1 (continued): Alcohol consumption ascertainment methods for 83 studies in the ERFC, EPIC-CVD and 
UK Biobank. 
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 Ex-drinkers at 
baseline 
 
Never-drinkers at 
baseline 
 
All current drinkers at 
baseline 
 
>0-≤50g/wk 
 
 
>50-≤100g/wk 
 
>100-≤150g/wk 
 
>150-≤250g/wk 
 
>250-≤350g/wk 
 
≥350g/wk 
 
Characteristics Subjects Mean (SD) 
/% 
Subjec
ts 
Mean (SD) 
/% 
Subjects Mean (SD) / 
% 
Subjects Mean (SD) 
/ % 
Subjects Mean (SD) 
/ % 
Subjects Mean (SD) / 
% 
Subject
s 
Mean (SD) / 
% 
Subjec
ts 
Mean (SD) 
/ % 
Subjec
ts 
Mean (SD) 
/ % 
Age at survey (years) 29,726 60.0 (8.8) 53,851 58.0 (9.8) 599,912 57.2 (8.7) 177,956 57.3 (9.3) 128,094 57.0 (8.6) 94,653 57.4 (8.4) 94,760 57.2 (8.2) 52,020 56.6 (8.2) 52,429 
 
56.4 (7.9) 
Sex 29,726  53,851  599,912  177,956  128,094  94,653  94,760  52,020  52,429  
      Male 14,542 48.9% 30% 39.6% 334,002 55.7% 70,698 39.7% 59,458 46.4% 53,158 56.2% 64,253 67.8% 40,332 77.5% 46,103 87.9% 
      Female 
 
15,184 51.1% 70% 70.4% 265,910 44.3% 107,258 60.3% 68,636 53.6% 
 
41,495 43.8% 30,507 32.2% 11,688 22.5% 6,326 12.1% 
 
Ethnicity 21,577  37,730  453,102  118,519  97,754  75,412  76,561  42,894  41,962  
      White 17,227 79.8% 19,585 52.2% 420,668 92.8% 106,584 89.9% 92,349 94.5% 71,898 95.3% 71,148 92.9% 39,600 92.3% 39,089 93.2% 
      Non-white 
 
4,350 20.1% 18,045 47.8% 32,434 7.2% 11,935 10.1% 5,405 5.5% 3,514   4.7% 5,413 7.1% 3,294 7.7% 2,873 6.9% 
Smoking status 29,726  53,851  599,912  177,956  128,094  94,653  94,760  52,020  52,429  
      Not current 23,618 79.5% 45,991 85.4% 471,827 78.7% 144,698 81.3% 106,747 83.3% 76,480 80.8% 73,888 78.0% 37,061 71.2% 32,953 62.9% 
      Current 
 
6,108 20.5% 7,860 14.6% 128,085 21.3% 33,258 18.7% 21,347   16.7% 18,173 19.2% 20,872 22.0% 14,959 28.8% 19,476 37.1% 
Level of education  25,540  36,845  519,896  155,700  112,538  82,316  81,392  43,992  43,958  
     No 
schooling/Primary 
2,359 9.2% 6,863 18.6% 43,468 8.4% 11,555 7.4% 4,859 4.3% 7,569 9.2% 4,319 5.3% 7,043 16.0% 8,123 18.5% 
     Secondary 13,696 53.6% 17,140 46.5% 208,928 40.2% 68,795 44.2% 43,851 39.0% 30,336 36.9% 31,087 38.2% 16,944 38.5% 17,915 40.8% 
     Vocational/ 
University 
 
9,485 37.1% 12,842 34.9% 267,500 51.4% 75,350 48.4% 
 
63,828 
 
56.7% 44,411 54.0% 45,986 56.5% 
 
20,005 45.5% 
 
17,920 40.8% 
 
Occupation 21,821  38,723  456,400  125,046  101,556  71,196  78,116  40,431  40,055  
      Not working 10,105 46.3% 17,732 45.8% 158,781 34.8% 46,712 37.4% 36,082 35.5% 24,915 35.0% 25,441 32.6% 12,911 31.9% 12,720 31.8% 
      Manual 2,292 10.5% 6,574 17.0% 54,701 12.0% 12,299 9.8% 8,729 8.6% 7,604 10.7% 9,910 12.7% 7,421 18.4% 8,738 21.8% 
      Office 6,389 29.3% 8,951 23.1% 189,885 41.6% 47,646 38.1% 45,163 44.5% 31,592 44.4% 35,221 45.1% 15,556 38.5% 14,707 36.7% 
      Other 
 
3,035 13.9% 5,466 14.1% 53,033 11.6% 18,389 14.7% 11,582 11.4% 7,085 10.0% 7,544 9.7% 4,543 11.2% 3,890 9.7% 
Total physical activity   1,253  1,962  23,796  9,756  4,926  2,539  3,051  1,734  1,790  
   Inactive 136 10.9% 102 5.2% 4,426 18.6% 1,335 13.7% 946 19.2% 586 23.1% 703 23.0% 453 26.1% 403 22.5% 
   Moderately inactive 329 26.3% 372 19.0% 7,484 31.5% 3,014 30.9% 1,532 31.1% 839 33.0% 964 31.6% 541 31.2% 594 33.2% 
   Moderately active 662 52.8% 1,279 65.2% 9,728 40.9% 4,483 46.0% 2,009 40.8% 904 35.6% 1,114 36.5% 583 33.6% 635 35.5% 
   Active 126 10.1% 209 10.7% 2,158 9.1% 924 9.5% 439 8.9% 210 8.3% 270 8.9% 157 9.1% 158 8.8% 
History of diabetes 29,726  53,851  599,912  177,956  128,094  94,653  94,760  52,020  52,429  
      No  26,932 90.6% 50,042 92.9% 577,650 96.3% 170,595 95.9% 124,004 96.8% 91,413 96.6% 91,479 96.5% 49,965 96.1% 50,194 95.7% 
      Yes 
 
2,794 9.4% 3,809 7.1% 22,262 3.7% 7,361 4.1% 4,090 3.2% 3,240 3.4% 3,281 3.5% 2,055 4.0% 2,235 4.3% 
SBP (mmHg) 
 
28,561 137 (20) 52,205 137 (20) 588,675 136 (19) 173,510 135 (19) 126,769 135 (19) 93,401 137 (19) 93,153 137 (18) 51,216 137.9 (18.5) 51,432 140 (19) 
HDL-C (mmol/l) 
 
13,208 1.31 (0.37) 26,611 1.38 (0.36) 221,727 1.38 (0.39) 79,285 1.34 (0.38) 38,518 1.38 (0.39) 32,916 1.40 (0.40) 27,485 1.40 (0.39) 20,895 1.43 (0.39) 22,628 1.44 (0.40) 
BMI (kg/m2) 28,862 26.2 (5.1) 52,735 26.5 (4.8) 589,621 26.1 (4.2) 173,729 26.0 (4.5) 126,769 25.8 (4.1) 92,837 25.9 (4.0) 93,807 26.0 (3.9) 51,072 26.2 (3.9) 51,407 26.4 (4.0) 
Total cholesterol 
(mmol/l) 
14,075 5.69 (1.10) 34,030 5.83 (1.10) 2503,32 5.81 (1.11) 88,335 5.77 (1.10) 43,479 5.79 (1.09) 36,149 5.81 (1.12) 32,083 5.83 (1.07) 24,083 5.89 (1.10) 26,203 5.90 (1.16) 
Fibrinogen (μmol/l) 6,129 9.21 (2.20) 17,726 8.99 (1.87) 89,957 9.01 (2.07) 28,845 9.20 (2.05) 16,048 9.01 (2.01) 12,011 8.94 (2.02) 15,207 8.98 (2.06) 8,411 8.90 (2.13) 9,435 8.80 (2.21) 
Smoking amount 13,447 18.6 (15.1) 41,553 6.74 (10.5) 252,036 17.0 (11.8) 81,518 13.1 (10.2) 55,050 16.3 (9.5) 39,147 18.1 (9.9) 34,339 20.0 (12.4) 21,812 21.5 (14.5) 20,170 25.8 (17.4) 
eTable 2: Summary of individual-level baseline characteristics, mortality and major cardiovascular outcomes by alcohol  
consumption categories.  
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Self-reported general 
health (0-1) 
17,704 0.59 (0.27) 22,366 0.60 (0.26) 382,490 0.64 (0.22) 109,540 0.64 (0.23) 90,195 0.66 (0.22) 62,584 0.67 (0.22) 64,568 0.65 (0.22) 28,343 0.62 (0.23) 27,260 0.60 (0.24) 
                   
All-cause mortality 3,777 12.9% 5,714 10.7% 40,317 6.9% 14,036 8.1% 7,479 6.0% 5,574 6.0% 5,475 5.9% 3,431 6.7% 4,322 8.4% 
All cardiovascular 
disease 
2,436 8.6% 3,763 7.3% 26,260 4.5% 8,665 5.2% 5,111 4.2% 3,682 4.0% 3,905 4.3% 2,347 4.7% 2,550 5.0% 
All stroke 813 2.7% 1,473 2.7% 12,098 2.0% 4,516 2.5% 2,412 1.9% 1,485 1.6% 1,582 1.7% 1,005 1.9% 1,098 2.1% 
Myocardial infarction 1,020 3.4% 1,378 2.6% 14,545 2.4% 5.458 3.1% 2,865 2.2% 1,809 1.9% 1,970 2.1% 1,172 2.3% 1,271 2.4% 
Coronary disease non-
MI 
484 1.6% 531 1.0% 8,039 1.3% 2,686 1.5% 1,639 1.3% 1,016 11% 1,270 1.3% 695 1.3% 733 1.4% 
Heart failure 461 1.6% 755 1.5% 2,748 0.5% 1,034 0.6% 492 0.4% 472 0.5% 351 0.4% 181 0.4% 218 0.4% 
Death from other type 
of cardiovascular 
diease 
106 0.4% 151 0.3% 1,160 0.2% 370 0.2% 192 0.2% 163 0.2% 157 0.2% 133 0.3% 145 0.3% 
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eTable 3: Summary of events for 83 studies, restricted to current drinkers. 
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Case-cohort studie                   
EPIC-CVD 26036 784 12758 5507 581 4926 3293 686 353 1146 5919 4963 - 2045 1675 370 - - - - - 
Nested case-control studies                  
FLETCHER 572 - 85 - - - - - - - - - - 85 - - - - - - - 
GLOSTRUP 313 14 63 - - - - - - - 61 47 14 2 2 - - - - - - 
HPFS 575 69 181 6 6 - 2 2 - 1 140 130 10 14 - 14 - - - 18 2 
WHIHABPS 108 108 84 71 2 69 71 - - - 9 9 - 3 - 3 - - - - - 
SUBTOTAL 1568 191 413 77 8 69 73 2 - 1 210 186 24 104 2 17 - - - 18 2 
Clinical trials                      
AFTCAPS 2566 46 117 14 - 14 5 - - 9 51 50 1 38 38 - 7 - - 5 - 
MRFIT 3453 239 218 18 4 14 1 - 1 15 170 142 28 12 - 12 4 5 1 - 2 
PROSPER 1710 104 181 45 2 43 - - - 45 82 82 - 16 - 16 33 - - - - 
WOSCOPS 5070 149 293 50 - 50 - - - 50 188 188 - 47 - 47 - - - - - 
SUBTOTAL 12799 538 809 127 6 121 6 - 1 119 491 462 29 113 38 75 44 5 1 5 2 
Prospective cohort studies                   
UKBIOBANK 326372 6720 7469 1616 108 1508 997 214 202 181 1953 1787 166 3404 3126 278 255 4 34 - 65 
 
0
ARIC 5987 1664 1365 352 30 322 273 37 18 15 361 314 47 44 - 44 542 10 25 - 7 
ATENA 3483 27 21 3 - 3 1 1 1 - 12 11 1 - - - - 2 2 - 1 
ATTICA 1053 22 13 - - - - - - - - - - - - - - - - - - 
AUSDIAB 2996 202 36 10 5 5 2 1 1 5 16 14 2 9 3 6 - - - - 1 
BHS 3052 647 276 70 70 - 5 6 - 51 94 - 94 68 - 68 10 4 4 - 10 
BRUN 404 142 73 29 11 18 21 8 - - 25 14 11 6 - 6 3 - - - 4 
BWHHS 1561 395 132 63 20 43 1 3 2 51 35 26 9 19 6 13 2 2 1 - 2 
CAPS 1878 307 224 15 15 - 3 - - 11 161 107 54 31 - 31 - - - - - 
CASTEL 2443 1072 514 101 101 - - - - 101 92 - 92 - - - 221 - - 72 - 
CHARL 142 100 24 5 - 5 - - - 5 12 7 5 - - - 6 - - - - 
CHS1 2286 1139 691 204 1 203 163 30 - 11 251 177 74 - - - 222 - - - - 
CHS2 209 79 52 17 - 17 15 1 - 1 17 12 5 - - - 17 - - - - 
COPEN 6552 2656 1613 470 41 429 295 56 13 94 342 342 - 615 615 - 43 4 16 9 11 
DESIR 3229 63 29 12 - 12 7 3 - 2 17 17 - - - - - - - - - 
DRECE 1824 107 24 5 5 - - 2 - 3 6 - 6 7 - 7 1 - 1 - - 
DUBBO 1299 463 309 104 2 102 44 11 2 45 126 126 - 38 - 38 15 4 - - 2 
EAS 697 314 133 59 28 31 1 5 2 43 41 22 19 14 - 14 7 1 5 - 1 
EPESEBOS 701 128 166 37 - 37 27 6 2 2 37 32 5 35 31 4 35 16 - - 1 
EPESEIOW 650 587 144 43 4 39 19 5 - 18 27 21 6 30 23 7 30 9 - - 1 
EPESENCA 389 241 81 27 3 24 15 3 - 9 21 19 2 14 9 5 15 4 - - - 
EPESENHA 497 102 131 25 1 24 18 3 - 4 26 25 1 20 20 - 22 25 1 - - 
ESTHER 4531 111 285 56 - 56 - - - 56 33 32 1 - - - 196 - - - - 
FINNMARK 2837 113 29 9 9 - 3 1 2 3 12 - 12 4 - 4 - 1 - - 2 
FINRISK92 3444 148 321 63 7 56 37 23 1 1 51 46 5 4 - 4 193 - 1 1 1 
FINRISK97 4256 118 325 48 2 46 36 10 - 2 45 40 5 4 - 4 219 - 1 - - 
FUNAGATA 214 8 15 12 1 11 8 3 - 1 3 3 - - - - - - - - - 
GREPCO 500 4 - - - - - - - - - - - - - - - - - - - 
HBS 46 30 5 1 1 - - - - 1 - - - 4 - 4 - - - - - 
HCS 2328 214 47 5 5 - - 1 1 3 10 - 10 11 - 11 2 - 2 - 9 
HIMS 5250 2017 938 288 32 256 140 47 3 88 308 235 73 169 132 37 133 6 9 - 10 
HISAYAMA 864 190 123 75 3 72 50 18 6 - 25 23 2 1 - 1 - 1 1 - 3 
HONOL 883 185 91 43 15 28 2 16 1 23 34 29 5 6 - 6 - 2 1 - 3 
HUBRO 11498 539 124 42 42 - 6 9 2 13 28 - 28 8 - 8 7 6 6 - 11 
IKNS 2701 358 188 131 12 119 69 24 5 33 30 14 16 4 - 4 18 1 - - 2 
KARELIA 41 31 28 5 1 4 1 - - 4 13 10 3 2 - 2 8 - - - - 
KIHD 1805 512 535 126 14 112 86 33 2 3 319 315 4 72 69 3 2 - 2 - 5 
LASA 1458 396 60 10 - 10 - - - 10 26 26 - - - - 24 - - - - 
MATISS83 2004 364 251 71 6 65 20 7 1 40 60 38 22 8 2 6 38 54 7 - - 
MATISS87 1401 182 122 37 - 37 7 3 1 26 30 14 16 2 - 2 18 27 3 1 - 
MATISS93 648 18 25 5 - 5 1 1 1 2 11 9 2 1 1 - 3 4 1 - - 
MCVDRFP 14655 1106 274 56 56 - 4 20 12 18 92 - 92 26 - 26 15 11 3 6 14 
MESA 2388 161 85 39 - 39 33 5 - 1 30 30 - 13 - 13 - - - - - 
MICOL 15563 382 116 23 23 - 4 2 - 15 53 - 53 32 - 32 - - - - 1 
MONICA_KORA1 757 124 85 5 5 - - 2 - 2 55 38 17 4 - 4 9 - - 1 2 
MONICA_KORA2 2655 177 83 3 3 - - - 1 2 63 41 22 7 - 7 6 - 1 1 - 
MONICA_KORA3 3022 378 177 30 30 - 8 8 - 13 104 81 23 21 - 21 4 2 - 7 - 
MRCOLD 4689 2736 1111 340 340 - 22 27 4 200 221 - 221 281 - 281 67 29 14 - 37 
NFR 2768 287 103 24 24 - 2 7 1 10 49 - 49 25 - 25 - - - - 3 
NHANESI 6828 1482 915 191 62 129 54 24 9 98 301 162 139 228 121 107 79 22 22 - 11 
NHANESIII 3677 753 225 51 51 - - - - 51 33 - 33 64 - 64 8 - 11 - 3 
NPHSII 2314 325 197 53 7 46 29 5 5 14 124 113 11 1 - 1 - - 3 10 5 
NSHS 708 46 46 13 1 12 - 1 - 12 3 - 3 30 30 - - - - - - 
OPPHED 5793 225 53 16 16 - 2 5 - 9 21 - 21 4 - 4 2 5 1 - - 
OSAKA 7521 290 108 61 8 53 21 14 4 22 20 16 4 1 - 1 21 1 1 1 2 
OSLO2 3824 701 164 45 45 - 6 16 3 16 42 - 42 18 - 18 13 9 6 - 8 
PRHHP 1439 188 80 10 7 3 5 4 - - 39 29 10 13 7 6 - - 6 7 3 
PRIME 7946 141 126 25 - 25 18 5 - 2 84 78 6 4 - 4 - - - 12 - 
PROCAM 10089 423 311 37 13 24 27 6 - 4 180 162 18 30 4 26 4 1 - 37 5 
QUEBEC 2113 543 414 89 4 85 - - - 89 253 229 24 14 - 14 6 - - 46 - 
RANCHO 1353 558 354 132 7 125 - 1 - 125 149 148 1 - - - 7 8 11 - 5 
RS_I 3145 820 440 144 70 74 20 14 2 102 141 120 21 - - - 38 - - 35 12 
RS_II 1119 117 80 17 7 10 2 2 - 13 45 45 - - - - 3 - - 9 1 
RS_III 2258 28 6 1 1 - - - - - - - - 1 - 1 - - - 1 1 
SHHEC 7919 417 410 88 5 83 21 11 12 41 208 168 40 100 86 14 1 1 1 2 4 
SHIP 1746 3 48 23 - 23 - - - 23 25 25 - - - - - - - - - 
TOYAMA 2480 68 57 30 - 30 12 13 5 - 21 21 - - - - 3 - - - - 
TROMS 1134 26 9 - - - - - - - 5 - 5 1 - 1 - 1 1 - 1 
TROMSØ 10024 862 592 244 9 235 178 29 23 11 301 272 29 12 - 12 3 2 4 10 6 
ULSAM 703 326 258 79 6 73 56 11 3 7 73 64 9 27 12 15 64 - 3 - 4 
WCWC 2310 222 12 - - - - - - - 12 12 - - - - - - - - - 
WHITEI 3099 1606 599 181 181 - 19 11 3 96 104 - 104 140 - 140 36 19 6 - 51 
WHITEII 8776 426 370 7 7 - 1 1 1 4 323 297 26 24 - 24 - - 1 - 3 
ZUTE 281 142 98 36 - 36 - - - 36 41 40 1 2 - 2 8 1 - 1 7 
SUBTOTAL 559509 38804 25038 6387 1583 4804 2917 835 357 1997 7925 6098 1827 5777 4297 1480 2704 299 218 269 341 
TOTAL 599912 40317 39018 12098 2178 9920 6289 1523 711 3263 14545 11709 1880 8039 6012 1942 2748 304 219 292 345 
TOTAL (excluding 
studies with fewer 
than 5 events for that 
particular outcome) 
599912 40317 39018 12090 2142 9910 6256 1482 663 3215 14539 11706 1852 7990 6000 1889 2711 261 178 283 289 
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eTable 4. Comparison of baseline characteristics of individuals used in main analysis versus individuals with repeat measures of alcohol consumption or measures of lifetime 
alcohol consumption from the contributing data sources. 
SD = standard deviation, BMI = body mass index, HDL-C = high density lipoprotein cholesterol.  
 ERFC  EPIC-CVD 
 
 UK Biobank  
 All participants Participants with 
repeat measures 
of alcohol 
consumption 
All participants Participants with 
measured lifetime 
alcohol consumption 
All participants Participants with repeat 
measures of alcohol 
consumption 
  
Number of studies/centres 81 studies  35 studies 22 centres  17 centres 1 study 1 study 
Known current drinkers at baseline, n (%) 247,504 38,472 26,036 18,779 326,372 13,760 
>0-≤25g/wk, n (%) 53,418 (21.6%) 5,734 (14.9%) 7,906 (30.4%) 5,247 (27.9%) 39,641 (12.2%) 1,320 (9.6%) 
>25-≤50g/wk, n (%) 33,953 (13.7%) 4,335 (11.3%) 3,704 (14.2%) 2,367 (12.6%) 39,334 (12.1%) 1,663 (12.1%) 
>50-≤75g/wk, n (%) 26,656 (10.8%) 3,591 (9.3%) 2,748 (10.6%) 1,867 (9.9%) 42,907 (13.2%) 1,864 (13.6%) 
>75-≤100g/wk, n (%) 16,557 (6.7%) 2,936 (7.6%) 2,446 (9.4%) 1,813 (9.7%) 36,780 (11.3%) 1,645 (12.0%) 
>100-≤150g/wk, n (%) 36,236 (14.6%) 5,617 (14.6%) 2,602 (10.0%) 1,883 (10.0%) 55,815 (17.1%) 2,551 (18.5%) 
>150-≤250g/wk, n (%) 31,645 (12.8%) 7,175 (18.7%) 3,090 (11.9%) 2,447 (13.0%) 60,025 (18.4%) 2,633 (19.1%) 
>250-≤350g/wk, n (%) 23,607 (9.5%) 4,289 (11.2%) 1,744 (6.7%) 1,507 (8.0%) 26,669 (8.2%) 1,131 (8.2%) 
≥350g/wk, n (%) 25,432 (10.3%) 4,795 (12.5%) 1,796 (6.9%) 1,648 (8.8%) 25,201 (7.7%) 953 (6.9%) 
  
Baseline alcohol consumption g/wk, median (5-
95th percentiles) 
87.7 (2.2-522.4) 128.3 (7-525) 61.9 (2.6-404.0) 73.8 (2.8-437.4) 103.9 (11.8-420.8) 106.5 (16.3-398.2) 
Age in years at baseline, mean (SD) 57.1 (8.7) 55.3 (8.3) 55.0 (9.2) 54.9 (8.7) 56.5 (8.0) 57.3 (7.3) 
Sex, n (%)       
      Male 162,685 (65.7%) 27,701 (72.0%) 13,508 (51.9%) 9,559 (51.1%) 157,809 (48.4%) 7,060 (51.3) 
      Female 84,819 (34.3%) 10,771 (28.0%) 12,528 (48.1%) 9,180 (48.9%) 168,563 (51.6%) 6,700 (48.7) 
Smoking status, n (%)       
      Not current 161,037 (65.1%) 25,319 (65.8%) 17,608 (67.6%) 12,693 (67.6%) 293,182 (89.8%) 12,918 (93.9%) 
      Current 86,467 (34.9%) 13,153 (34.2%) 8,428 (32.4%) 6,086 (32.4%) 33,190 (10.2%) 842 (6.1%) 
History of diabetes, n(%)       
      No 237,685 (96.0%) 36,936 (96.0%) 24,875 (95.5%) 17,889 (95.3%) 315,090 (96.5%) 13,334 (96.9%) 
      Yes 9,819 (4.0%) 1,536 (4.0%) 1,161 (4.5%) 890 (4.7%) 11,282 (3.5%) 426 (3.1%) 
BMI in kg/m2, mean (SD) 26.1 (3.8) 26.0 (3.5) 26.4 (4.1) 26.7 (4.2) 27.0 (4.4) 26.6 (4.2) 
HDL-C in mmol/l, mean (SD) 1.40 (0.41) 1.41 (0.40) 1.40 (0.42) 1.41 (0.43) not available not available 
Total cholesterol in mmol/l, mean (SD)  5.80 (1.17) 5.77 (1.05) 6.11 (1.16) 0.12 (1.16) not available not available 
Systolic blood pressure in mmHg, mean(SD)   136.5 (19.0) 134.4 (17.5) 138.4 (21.3) 137.9 (21.1) 137.9 (18.5) 137.5 (17.8) 
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eTable 5. Hazard ratios for cardiovascular outcomes amongst current drinkers, without and with 
adjustment for usual levels of potential confounders, mediators and proxies thereof.  
Level of adjustment 
HR (95% CI) per 100 grams/week higher average alcohol consumption 
All stroke Myocardial infarction 
Coronary disease  
(non-MI) 
Heart failure  
Deaths from other types 
of cardiovascular disease 
No. of cohorts / events 8 / 465 10 / 1,055 7 / 327 3 / 74 3 / 90 
Basic adjustment* 1.23  (1.09, 1.38) 1.00 (0.93, 1.08) 1.15 (1.00, 1.33) 1.03 (0.52, 2.00) 1.48 (0.93, 2.37) 
+ plus LDL cholesterol 1.24 (1.11, 1.38) 1.04 (0.95, 1.12) 1.17 (0.98, 1.41) 0.99 (0.49, 1.98) 1.54 (0.95, 2.51) 
      
No. of cohorts / events 59/ 3,986 64 / 5,690 38 / 1,916 31 / 2,082 38 / 826 
Basic adjustment* 1.17 (1.10, 1.23) 0.95 (0.90, 1.00) 1.08 (1.01, 1.17) 1.12 (1.02, 1.23) 1.13 (1.00, 1.27) 
+ total cholesterol 1.17 (1.11, 1.23) 0.93 (0.89, 0.97) 1.07 (0.99, 1.16) 1.13 (1.03, 1.25) 1.19 (1.05, 1.35) 
      
No. of cohorts / events 31 / 2,236 34 / 3,007 22 / 1,236 16 / 1,099 18 / 303 
Basic adjustment* 1.14 (1.07, 1.21) 0.94 (0.89, 1.00) 1.12 (0.99, 1.26) 1.16 (0.99, 1.35) 1.20 (1.10, 1.32) 
+ fibrinogen 1.13 (1.08, 1.18)  0.97 (0.92, 1.03) 1.12 (1.01, 1.25) 1.25 (1.07, 1.46) 1.24 (1.10, 1.40) 
      
No. of cohorts / events 53 / 2,649 59 / 3,241 29 / 1,809 26 / 1,211 30 / 453 
Basic adjustment* 1.10 (1.05, 1.15) 0.93 (0.88, 0.97) 1.05 (0.98, 1.12) 1.05 (1.00, 1.11) 1.20 (1.10, 1.31) 
+ smoking amount 1.09 (1.04, 1.15) 0.92 (0.88, 0.97) 1.03 (0.95, 1.10) 1.02 (0.97, 1.08) 1.19 (1.09, 1.30) 
      
No. of cohorts / events 30 / 8,055 32 / 9,238 21 / 5,795 18 / 1,570 18 / 420 
Basic adjustment* 1.13 (1.09, 1.17) 0.92 (0.86, 0.99) 1.05 (0.93, 1.20) 1.08 (0.99, 1.17) 1.22 (1.07, 1.38) 
+ education level and 
occupation 
1.13 (1.09, 1.18) 0.92 (0.87, 0.99) 1.05 (0.92, 1.19) 1.07 (0.98, 1.17) 1.22 (1.07, 1.40) 
      
No. of cohorts / events 1 / 4,916 1 / 5,291 1 / 2,006 - - 
Basic adjustment* 1.17 (1.11, 1.21) 0.89 (0.85, 0.93) 0.98 (0.90, 1.07)   
+ physical activity 1.16 (1.11, 1.21) 0.89 (0.85, 9093) 0.98 (0.90, 1.07)   
      
No. of cohorts / events 24 / 2,717 24 / 3,006 24 / 4,427 24 / 1,071 24 / 296 
Basic adjustment* 1.13 (1.10, 1.16) 0.95 (0.91, 0.98) 1.01 (0.98, 1.04) 1.14 (1.08, 1.20) 1.16 (1.08, 1.24) 
+ self-reported general 
heath 
1.12 (1.09, 1.16) 0.94 (0.91, 0.98) 1.00 (0.97, 1.03) 1.13 (1.06, 1.19) 1.15 (1.07, 1.24) 
      
No. of cohorts / events 1 / 1,608 1 / 1,945 1 / 3370 1 / 254 
 
1 / 103 
Basic adjustment* 1.11 (1.07, 1.15) 0.94 (0.90, 0.98) 1.00 (0.97, 1.04) 1.07 (0.97, 1.19) 1.17 (1.09, 1.26) 
+ Red meat consumption1 1.11 (1.07, 1.15) 0.93 (0.89, 0.97) 1.00 (0.97, 1.03) 1.05 (0.95, 1.16) 1.17 (1.08, 1.27) 
     
No. of cohorts / events 57 /4114 57 /4,717 35 / 2175 33 / 1680 37 / 842 
Basic adjustment* 1.17 (1.11, 1.23) 0.92 (0.87, 0.97) 1.09 (1.03, 1.15) 1.13 (1.06, 1.21) 1.17 (1.01, 1.37) 
+ anti-hypertensive drug 
use2 
1.17 (1.11, 1.23) 0.92 (0.87, 0.97) 1.08 (1.02, 1.15) 1.14 (1.06, 1.22) 1.17 (1.00, 1.36) 
     
       
 
Analyses restricted to individuals with basic adjustment variables plus the additional variable. Studies 
with fewer than five events were excluded from the analysis of each outcome. *Basic adjustment 
includes age, smoking and history of diabetes, and stratified by sex and EPIC centre. 1Adjustment 
includes separate varibles for pork, beef and lamb consumption. 2Adjustment includes systolic blood 
pressure, anti-hypertinsive drug use and their interaction.  
 
 
 
 
eTable 6. Hazard ratios for death from lung cancer and digestive related cancer outcomes per 100 
grams/wk higher average alcohol consumption amongst current drinkers, without and with adjustment 
for potential confounders, mediators and proxies thereof.  
 
 
Level of adjustment Deaths from lung cancer 
 Death from digestive related 
cancer 
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No. of  
cohorts / 
events 
HR (95% CI) 
 
No. of  
cohorts / 
events 
HR (95% CI) 
Basic adjustment* 49 / 2,530 1.18 (1.10, 1.27)  55 / 3,747 1.17 (1.12, 1.24) 
+ systolic blood pressure  1.18 (1.10, 1.26)   1.17 (1.11, 1.22) 
      
Basic adjustment* 39 / 1,356 1.17 (1.07, 1.29)  45 / 1,768 1.19 (1.11, 1.26) 
+ plus HDL cholesterol  1.20 (1.08, 1.33)   1.18 (1.12, 1.25) 
      
Basic adjustment* 49 / 2,490 1.18 (1.10, 1.26)  53 / 3,686 1.16 (1.10, 1.24) 
+ body mass index  1.18 (1.10, 1.26)   1.16 (1.10, 1.24) 
     
Basic adjustment* 45 / 1,561 1.17 (1.08, 1.27)  49 / 2,056 1.17 (1.10, 1.24) 
+ total cholesterol  1.17 (1.07, 1.27)   1.17 (1.10, 1.24) 
     
Basic adjustment* 19 / 1,926 1.13 (1.02, 1.24)  19 / 1,922 1.17 (1.09, 1.26) 
+ education and occupation 
 1.11 (1.01, 1.12)  
 1.15 (1.08, 1.22) 
     
Basic adjustment* 24 / 838 1.09 (1.04, 1.15)  43 / 1,517 1.15 (1.08, 1.22) 
+ smoking amount  1.04 (0.98, 1.09)   1.14 (1.07, 1.21) 
      
 
Analyses restricted to individuals with basic adjustment variables plus the additional variable. Studies 
with fewer than five events were excluded from the analysis of each outcome. *Basic adjustment 
includes age, smoking status and history of diabetes, and stratified by sex and EPIC centre.  Digestive 
cancers were defined as tumours of the liver, colorectum, stomach, pancreas and oesophagus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 7: Sex-specific hazard ratios for major cardiovascular outcomes per 100 grams/week increase 
in average alcohol consumption amongst current drinkers.  
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Studies with fewer than five events were excluded from the analysis of each outcome. *Adjusted for 
age, smoking and history of diabetes, and stratified by sex and EPIC centre.   
  
Description of sensitivity 
analyses 
Outcome No. of events Hazard Ratio (95% CI) 
per 100 grams/week 
increase 
I2 (95% CI) 
 
Restricted to men  
    
All stroke 7280 1.15 (1.10, 1.19) 17% (0%, 39%) 
 Myocardial infarction 11068 0.95 (0.93, 0.98) 5% (0%, 29%) 
 Coronary disease non-MI 5591 1.05 (1.00, 1.11) 23% (0%, 47%) 
 Heart failure 1663 1.10 (1.05, 1.15) 1% (0%, 39%) 
 Deaths from other types of  
cardiovascular disease 
795 1.17 (1.06, 1.29) 30% (9%, 53%) 
     
Restricted to women  All stroke 4704 1.09 (1.01, 1.18) 3% (0%, 29%) 
Myocardial infarction 3407 0.87 (0.75, 1.01) 28% (0%, 52%) 
 Coronary disease non-MI 2349 1.07 (0.86, 1.33) 54% (23%, 72%) 
 Heart failure 1010 0.94 (0.82, 1.08) 0% (0%, 45%) 
 Deaths from other types of  
cardiovascular disease 
287 1.45 (1.10, 1.92) 197% (0%, 53%) 
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eTable 8: Sensitivity analyses: Hazard ratios for major cardiovascular outcomes per 100 grams/week 
increase in average alcohol consumption amongst current drinkers.  
 
 
Studies with fewer than five events were excluded from the analysis of each outcome. *Adjusted for 
age, smoking and history of diabetes, and stratified by sex and EPIC centre.   
  
Description of sensitivity 
analyses 
Outcome No. of events Hazard Ratio (95% CI) 
per 100 grams/week 
increase 
I2 (95% CI) 
Principal analysis on all 
individuals 
All stroke 12090 1.14 (1.10, 1.17) 12% (0%, 35%) 
Myocardial infarction 14539 0.94 (0.91, 0.97) 12% (0%, 35%) 
 Coronary disease non-MI 7990 1.06 (1.00, 1.11) 26% (0%, 49%) 
 Heart failure 2711 1.09 (1.03, 1.15) 4% (0%, 31%) 
 Deaths from other types of  
cardiovascular disease 
1121 1.18 (1.07, 1.30) 33% (2%, 53%) 
     
     
Excluding first five years of 
follow-up 
All stroke 8005 1.14 (1.10, 1.18) 6% (0%, 32%) 
Myocardial infarction 8880 0.94 (0.91, 0.97) 0% (0%, 29%) 
 Coronary disease non-MI 3989 1.06 (1.02, 1.10) 0% (0%, 37%) 
 Heart failure 1821 1.09 (1.04, 1.14) 0% (0%, 38%) 
 Deaths from other types of  
cardiovascular disease 
808 1.17 (1.07, 1.28) 6% (0%, 36%) 
     
Excluding current smokers All stroke 8185 1.15 (1.12, 1.18) 0% (0%, 30%) 
Myocardial infarction 8880 0.95 (0.93, 0.98) 0% (0%, 28%) 
 Coronary disease non-MI 5994 1.07 (0.98, 1.17) 40% (12%, 59%) 
 Heart failure 1926 1.14 (1.06, 1.23) 14% (0%, 44%) 
 Deaths from other types of  
cardiovascular disease 
679 1.20 (1.09, 1.32) 6% (0%, 35%) 
     
     
Excluding people with a 
history of diabetes 
All stroke 11089 1.13 (1.10, 1.17) 8% (0%, 33%) 
Myocardial infarction 13418 0.95 (0.91, 0.98) 25% (0%, 44%) 
 Coronary disease non-MI 7365 1.06 (1.01, 1.11) 23% (0%, 47%) 
 Heart failure 2351 1.13 (1.05, 1.21) 15% (0%, 44%) 
 Deaths from other types of  
cardiovascular disease 
1022 1.17 (1.06, 1.30) 36% (7%, 56%) 
     
Excluding people with a 
history of cancer 
All stroke 6528 1.10 (1.07, 1.12) 0% (0%, 50%) 
Myocardial infarction 7306 0.94 (0.90, 0.98) 11% (0%, 48%) 
Coronary disease non-MI 4744 1.10 (0.98, 1.24) 64% (37%, 79%) 
Heart failure 1145 1.05 (1.01, 1.10) 0% (0%, 57%) 
Deaths from other types of  
cardiovascular disease 
379 1.21 (1.07, 1.36) 31% (0%, 64%) 
     
Excluding non-European 
descents 
All stroke 3870 1.15 (1.09, 1.21) 17% (0%, 44%) 
Myocardial infarction 5680 0.95 (0.92, 1.00) 17% (0%, 54%) 
Coronary disease non-MI 4219 1.01 (0.98, 1.04) 0% (0%, 41%) 
 Heart failure 2118 1.06 (1.00, 1.14) 10% (0%, 43%) 
 Deaths from other types of  
cardiovascular disease 
673 1.08 (0.97, 1.20) 17% (0%, 48%) 
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eTable 9: Baseline characteristics by frequency of alcohol consumption 
 
Baseline characteristic Drinks ≤ 2 days per week Drinks >2 days per week 
 n Mean (SD) or % n Mean (SD) or % 
Age in years 194,346 57.0 (8.9) 244,903 58.0 (8.2) 
Sex 194,346  244,903  
  Male 89,157 45.9% 143,471 58.6% 
  Female 105, 189 54.1% 101,432 41.4% 
Ethnicity 161,710  207,898  
      White 152,516 94.3% 201,651 97.0% 
      Non-white 9,194 5.7% 6,247 3.0% 
Smoking status 194,346  244,903  
      Not current 164,285 84.5% 204,092 83.3% 
      Current 30,061 15.5% 40,811 16.7% 
Level of education  184,511  223,938  
     No schooling/Primary 4,789 2.6% 4,355 1.9% 
     Secondary 81,783 44.3% 79,879 35.7% 
     Vocational/ University 97,939 53.1% 139,704 62.4% 
Occupation 163,956  214,731  
      Not working 58,453 35.7% 80,291 37.4% 
      Manual 20,372 12.4% 22,457 10.5% 
      Office 71,846 43.8% 97,588 45.5% 
      Other 13,285 8.1% 14,395 6.7% 
History of diabetes 194,346  244,903  
      No history  186,451 95.9% 237,473 97.0% 
      Definite diabetic 7,895 4.1% 7,430 3.0% 
Average total household income 
before tax 
118,864  164,772  
 Less than £18,000 25,335 21.3% 23,749 14.4% 
 £18,000 to £30,999 30,965 26.0% 38,241 23.2% 
 £31,000 to £51,999 32,899 27.7% 46,141 28.0% 
 £52,000 to £100,000 24,416 20.5% 42,983 26.1% 
 Greater than £100,000 5,248 4.4% 13,658 8.3% 
Townsend deprivation index 139,416 -1.36 (3.0) 186,555 -1.71 (2.8) 
Systolic blood pressure (mmHg) 192,672 135.5 (18.6) 243,256 138.0 (18.6) 
HDL-C (mmol/l) 45,830 1.33 (0.37) 46,369 1.42 (0.39) 
BMI (kg/m2) 190,908 26.4 (4.6) 242,299 26.2 (4.0) 
Total cholesterol (mmol/l) 50,430 5.80 (1.11) 51,966 5.88 (1.12) 
Fibrinogen (μmol/l) 13,162 9.14 (2.10) 18,627 8.80 (2.23) 
Smoking amount 85,184 14.3 (6.3) 85,179 20.2 (8.5) 
Self-reported general health (0-
1) 
170,928 0.64 (0.23) 204,404 0.67 (0.22) 
Alcohol consumption (g/wk) 194,346 49.1 (59.4) 244,903 181.1 (156.6) 
Wine consumption (g/wk) 157,209 23.8 (33.0) 202,332 104.4 (95.9) 
Beer consumption (g/wk) 157,032 26.3 (54.1) 202,777 94.2 (135.9) 
Spirits consumption (g/wk) 154,814 16.8 (25.6) 201,022 52.4 (56.2) 
 
 
SD = standard deviation, BMI = body mass index, HDL-C = high density lipoprotein cholesterol. 
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eTable 10: Baseline characteristics by type of alcohol predominantly consumed* 
 
Baseline characteristic Predominantly wine drinkers Predominantly beer  drinkers Predominantly spirits 
drinkers 
 n Mean (SD) or % n Mean (SD) or % n Mean (SD) or % 
Age in years 203,900 58.0 (8.1) 106,464 56.0 (8.3) 120,069 57.0 (8.2) 
Sex 203,900  106,464  120,069  
  Male 78,360 38.4% 86,039 80.8% 55,924  46.6% 
  Female 125,540 61.6% 20,425 19.2% 64,145 53.4% 
Ethnicity 189,411  92,549  102,642  
      White 183,828 97.1% 89,832 97.1% 98,383 95.9% 
      Non-white 5,583 3.0% 2,717 2.9% 4,259 4.1% 
Smoking status 203,900  106,464  120,069  
      Not current 180,169 88.4% 85,087  79.9% 94,955 79.1% 
      Current 23,731 11.6% 21,377 20.1% 25,114 20.9% 
Level of education  195,833  100,048  112,894  
     No schooling/Primary 15,820 8.1% 5,749 5.8% 10,483 9.3% 
     Secondary 59,631 30.5% 40,335 40.3% 45,623 40.4% 
     Vocational/University 120,382 61.5% 53,964 53.9% 56,788 50.3% 
Occupation 182,414  96,134  102,561  
      Not working 69,651 38.2% 30,092 31.3% 41,597 40.6% 
      Manual 9,440 5.2% 17,132 17.8% 9,687 9.5% 
      Office 84,116 46.1% 38,525 40.1% 39,127 38.2% 
      Other 19,207 10.5% 10,385 10.8% 12,150 11.9% 
History of diabetes 203,900  106,464  120,069  
      No history  197,875 97.0% 102,097 95.9% 115,272 96.0% 
      Definite diabetic 6,025 3.0% 4,367 4.1% 4,797 4.0% 
Average total household income 
before tax 
141,379  71,216  69,144  
 Less than £18,000 19,309 13.7% 14,677 20.6% 14,392 20.8% 
 £18,000 to £30,999 32,276 22.8% 17,912 25.2% 18,451 26.7% 
 £31,000 to £51,999 39,569 28.0% 20,330 28.6% 18,735 27.1% 
 £52,000 to £100,000 37,990 26.9% 15,431 21.7% 13,803 20.0% 
 Greater than £100,000 12,235 8.7% 2,866 4.0% 3,763 5.4% 
Townsend deprivation index 161,484 -1.83 (2.75) 80,645 -1.23 (3.06) 81,049 -1.42 (3.00) 
Systolic blood pressure (mmHg) 201,083 133.5 (18.9) 105,227 134.4 (17.9) 118,057 135.6 (18.8) 
HDL-C (mmol/l) 36,838 1.41 (0.39) 20,238 1.32 (0.36) 32,713 1.38 (0.39) 
BMI (kg/m2) 200,656 26.3 (4.2) 105,454 26.1 (4.2) 117,864 26.4 (4.4) 
Total cholesterol (mmol/l) 40,035 5.70 (1.16) 23,720 5.62 (1.13) 36,126 5.79 (1.15) 
Fibrinogen (μmol/l) 4,314 9.35 (1.94) 4,664 9.61 (2.11) 7,298 9.48 (1.94) 
Smoking amount 90,512 11.4 (7.8) 39,733 17.9 (8.4) 46,883 18.3 (11.3) 
Self-reported general health (0-1) 165,686 0.63 (0.23) 84,686 0.62 (0.23) 86,272 0.64 (0.23) 
Alcohol consumption (g/wk) 203,900 138 (132) 106,464 153 (171) 120,069 191 (161) 
 
SD = standard deviation, BMI = body mass index, HDL-C = high density lipoprotein cholesterol. 
* Type of alcohol predominantly consumed was determined from the maximum baseline consumption 
grams/week for each alcohol type. 
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eFigure 1: Flow diagram of study selection process in current analysis 
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eFigure 2: Box plots of baseline alcohol consumption amongst 599,912 current drinkers from 83 studies by decade of first baseline survey.  
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eFigure 3a: Cross-sectional associations between baseline alcohol consumption and continuous 
baseline characteristics.  
 
 
Response means are adjusted to age 50 year and plotted at deciles of baseline alcohol consumption. Red squares and solid lines represent 
associatons for females; blue squares and dashed lines represent associatons for males. The r values represent the age and sex adjusted partial 
correlation coefficient (95% CI) between continuous baseline characteristics and alcohol consumption in males and females combined. The Y-axis 
is labelled at the mean and +/- two standard deviations of the baseline characteristic of interest. BMI: Body mass index, SBP: systolic blood 
pressure, HDL-C:high density lipoprotein cholesterol. Error bars present 95% CI.  
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eFigure 3b: Cross-sectional associations between baseline consumption and categorical baseline characteristics. 
Response means are adjusted to age 50 years. Red squares represent associatons for females; blue 
squares represent associatons for males. Error bars present 95% CI.  
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eFigure 4: Shape of association of average alcohol consumption with all-cause mortality and all 
cardiovascular disease amongst current drinkers. 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Studies with 
fewer than five events of any outcome were excluded from the analysis of that outcome. The sizes of 
the boxes are proportional to the inverse of the variance of the log-transformed hazard ratios. The 
reference category is the lowest alcohol consumption category (>0 and <25g/week). 
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eFigure 5. Shape of association of baseline alcohol consumption with all-cause mortality for males and 
females.  
 
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. The reference 
category is the lowest alcohol consumption category (>0 and <25g/week). Sizes of the boxes are 
proportional to the inverse of the variance of the log-transformed hazard ratios. 
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eFigure 6. Shape of association of baseline alcohol consumption with all-cause mortality by age-specific groups.  
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. The reference category is the lowest alcohol consumption category (>0 and 
<25g/week). Sizes of the boxes are proportional to the inverse of the variance of the log-transformed hazard ratios.  
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eFigure 7. Shapes of associations of baseline alcohol consumption with fatal and non-fatal major cardiovascular causes.  
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Alcohol consumption categories amongst current drinkers were >0-≤50 grams/week, 
>50-≤100 grams/week, >100-≤150 grams/week, >150-≤250 grams/week, >250-≤350 grams/week and >350 grams/week. The reference category is the lowest alcohol 
consumption category (>0 and <50g/week). Studies with fewer than five events of any outcome were excluded from the analysis of that outcome. The sizes of the boxes are 
proportional to the inverse of the variance of the log-transformed hazard ratios.  
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eFigure 8. Shapes of associations of baseline alcohol consumption with type of stroke.  
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Alcohol 
consumption categories amongst current drinkers were >0-≤50 grams/week, >50-≤100 grams/week, >100-
≤150 grams/week, >150-≤250 grams/week, >250-≤350 grams/week and >350 grams/week. The reference 
category is the lowest alcohol consumption category (>0 and <50g/week). Studies with fewer than five 
events of any outcome were excluded from the analysis of that outcome. Sizes of the boxes are proportional 
to the inverse of the variance of the log-transformed hazard ratios.  
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eFigure 9a: Hazard ratios per 100 grams/week higher average alcohol consumption for subtypes 
of cardiovascular outcomes amongst current drinkers, adjusted for body mass index. 
 
eFigure 9b. Shape of association of average alcohol consumption with all-cause  
mortality and all cardiovascular disease amongst current drinkers, adjusted for body mass index. 
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eFigure 10: Shape of association between baseline alcohol consumption, including ex- and non-drinkers, with all cardiovascular disease and all-cause mortality.  
 
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Studies with fewer than five events of the outcome were excluded from the analysis. 
The sizes of the boxes are proportional to the inverse of the variance of the log-transformed hazard ratios Alcohol consumption categories amongst current drinkers were >0-
≤50 grams/week, >50-≤100 grams/week, >100-≤150 grams/week, >150-≤250 grams/week, >250-≤350 grams/week and >350 grams/week. The reference category is the 
lowest alcohol consumption category (>0 and <50g/week).  Individuals for whom we were unable to distinguish as ex- or never- drinkers were excluded from the analysis.  
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eFigure 11: Hazard ratios per 100 grams/week higher baseline alcohol consumption for subtypes of cardiovascular outcomes amongst current drinkers with 
recorded baseline alcohol consumption (left) compared against all current drinkers using multiple imputation (right).
 
Missing alcohol consumption (log transformed) for known current drinkers was imputed using standard multiple imputation methods separately within each study, using 
known predictors for age, gender, smoking status, history of diabetes, indicators for CVD disease categories listed in table above and corresponding Nelson-Aalen estimators, 
weighted appropriately for the sampling fraction in EPIC-CVD (see  White, I. R., Royston, P. and Wood, A. M. (2011), Multiple imputation using chained equations: Issues 
and guidance for practice. Statist. Med., 30: 377–399. doi:10.1002/sim.4067). Twenty imputed datasets were created for each study. The analysis was then performed 
separately by study, pooling imputation-specific estimates using Rubin’s rules. This was followed by a random-effects meta-analysis.  
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eFigure 12: Shapes of associations of average alcohol consumption with stroke and coronary outcomes 
amongst alcohol drinkers 
 
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Alcohol 
consumption categories amongst current drinkers were >0-≤50 grams/week, >50-≤100 grams/week, 
>100-≤150 grams/week, >150-≤250 grams/week, >250-≤350 grams/week and >350 grams/week. The 
reference category is the lowest alcohol consumption category (>0 and <50g/week). Studies with fewer 
than five events of any outcome were excluded from the analysis of that outcome. Sizes of the boxes 
are proportional to the inverse of the variance of the log-transformed hazard ratios.  
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eFigure 13: Best fitting 2nd degree fractional polynomial for the modelled shape of association between 
baseline alcohol consumption with all-cause mortality.  
 
 
To estimate the alcohol consumption level at which mortality risk was lowest (i.e., the association’s 
nadir) we conducted nonlinear modelling by fitting a Cox regression model stratified by cohort, sex, and 
trial arm (where applicable), to determine a best fitting second degree fractional polynomial model (FP2) 
for alcohol. Using the fitted model parameters we estimated the nadir as the alcohol consumption level 
at which the first derivative of the best-fitting FP2 function equalled zero. 
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eFigure 14: Hazard ratios per 100 grams/week higher average alcohol consumption for 
subtypes of cardiovascular outcomes amongst current drinkers from a fixed effect meta-
analysis. 
 
 
 
Adjusted for age, smoking and history of diabetes. *Studies of the same design (ie, prospective, case-
cohort and nested case-control studies) were analysed together in a single model, stratified by cohort, 
sex, EPIC centre. Results from each study design were then combined in a fixed-effects meta-analysis.   
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eFigure 15: Hazard ratios per 100 grams/week higher average alcohol consumption for 
subtypes of cardiovascular outcomes amongst current drinkers, from fixed effects analysis 
with inclusion of studies with fewer than 5 outcomes of a particular type*. 
 
 
Adjusted for age, smoking and history of diabetes.  
*Studies of the same design (ie, prospective, case-cohort and nested case-control studies) were 
analysed together in a single model, stratified by cohort, sex, EPIC centre. Results from each study 
design were then combined in a fixed-effects meta-analysis. This analysis approach enabled inclusion 
of all studies that recorded fewer than 5 outcomes of a particular type.  
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eFigure 16: Shapes of associations of baseline alcohol consumption with stroke and coronary 
outcomes amongst alcohol drinkers restricted to studies recording both fatal and non-fatal endpoints.  
 
 
 
 
Analysis restricted to studies recording fatal and non-fatal vascular diseases. Adjusted for age, smoking 
and history of diabetes, and stratified by sex and EPIC centre. Alcohol consumption categories amongst 
current drinkers were >0-≤50 grams/week, >50-≤100 grams/week, >100-≤150 grams/week, >150-≤250 
grams/week, >250-≤350 grams/week and >350 grams/week. The reference category is the lowest 
alcohol consumption category (>0 and <50g/week). Studies with fewer than five events of any outcome 
were excluded from the analysis of that outcome. The sizes of the boxes are proportional to the inverse 
of the variance of the log-transformed hazard ratios. 
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eFigure 17: Shapes of associations of baseline alcohol consumption with all-cause mortality by (a) consumption frequency, (b) consumption type* and (c) binge drinking 
status. 
 
 
 
 
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre.  
 
*Analysis was performed separately for each alcohol consumption type (351,342 wine drinkers; 227,469 beer drinkers; 171,770 spirits drinkers). Individuals drinking more 
than one type of alcohol were included in each separate analysis. 
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eFigure 18. Hazard ratios per 100 grams/week higher baseline alcohol consumption for major 
cardiovascular outcomes amongst current drinkers and by alcohol type. 
 
 
  
Analyses were restricted to 430,433 individuals with known alcohol type (351,342 wine drinkers; 227,469 beer drinkers; 
171,770 spirits drinkers).  
 
Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Indicator variables for 
consumption-type were also included in the models.   
Studies with fewer than five events of any outcome were excluded from the analysis of that outcome.  
P-value1 for difference in hazard ratios for beer versus wine and spirits versus wine. Comparisons were restricted to 
beer and wine drinkers and spirits and wine drinkers respectively.  
P-value2 for difference in hazard ratios for beer versus spirits. Comparison was restricted to beer and spirits drinkers.  
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eFigure 19a-e: Hazard ratios per 100 gram/week increase in usual alcohol consumption for major vascular outcomes 
amongst current drinkers by study/cohort-level characteristics.  
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Adjusted for age, smoking and history of diabetes, and stratified by sex and EPIC centre. Studies with fewer than five 
events of any outcome were excluded from the analysis of that outcome. The sizes of the boxes are proportional to the 
inverse of the variance of the log-transformed hazard ratios. 
Geographical “region” other includes studies in Australia and New Zealand. Studies from Japan were exlcuded. The 
studies included in this analysis recruited participants over different calendar periods (ERFC: 1964-2008; EPIC-CVD: 
1990-2002; UK Biobank: 2005-2014).
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eFigure 20a-e: Hazard ratios per 100 gram/week higher average alcohol consumption for major cardiovascular 
outcomes amongst current drinkers by individual-level characteristics. 
 45 
 
 
 46 
 
 
HRs were adjusted for age, smoking and history of diabetes and stratified by EPIC centre. BMI = body 
mass index; bottom third <24.10 kg/m2, middle third 24.10-27.18 kg/m2, top third >27.18kg/m2. SBP = 
systolic blood pressure; bottom third <123 mmHg, middle third 123-141mmHg, top third>141mmHg. 
HDL-c bottom third <1.10 mmol/l, middle third 1.19-1.51mmol/l and top third >1.51 mmol/l. Self-
reported general health bottom half <0.67,  top half>=0.67.  
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eFigure 21. Funnel plots and assessment of small-study effects for study-specfic hazard ratios per 100 gram/week increase in usual alcohol consumption for major  
vascular outcomes amongst current drinkers. 
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eFigure 22. Estimated future years of life lost in individuals drinking above a range of 
hypothetical alcohol consumption thresholds compared to those drinking less than the 
hypothetical alcohol consumption thresholds.  
 
 
 
 
 
Interpretation: 40-year old males drinking above 196 g/wk threshold have approximately 2.7-years 
(95% CI: 2.4-3.1) lower life expectancy than those drinking below 196 g/wk. Similarly, 40-year old 
males drinking above 112 g/wk threshold have approximately 1.6-years (95% CI: 1.3-1.8) lower life 
expectancy than those drinking below 100 g/wk.  
 
The estimates of cumulative survival from 40 years of age onward among the drinking groups were 
calculated by applying hazard ratios (specific to age at risk) for all-cause mortality associated with 
baseline alcohol consumption to US death rates at the age of 40 years or older. 
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